化疗引起的恶心和呕吐：是时候更加强调恶心了吗？
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
作者信息
Ng Terry L, Hutton Brian, Clemons Mark
机构信息
Division of Medical Oncology, Department of Medicine, and Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; Ottawa Hospital Research Institute, Ottawa, Canada
Division of Medical Oncology, Department of Medicine, and Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; Ottawa Hospital Research Institute, Ottawa, Canada.
出版信息
Oncologist. 2015 Jun;20(6):576-83. doi: 10.1634/theoncologist.2014-0438. Epub 2015 May 6.
Abstract
Despite advances in antiemetic therapy, chemotherapy-induced nausea and vomiting (CINV) remains the most feared and expected side effect of chemotherapy. Optimization of antiemetic therapy is important because CINV can lead to reduced quality of life, increased use of health care resources, and compromised treatment adherence. The evidence illustrates how antiemetic recommendations have evolved and raises ongoing issues and controversies in the management of CINV.
摘要
尽管在止吐治疗方面取得了进展，但化疗引起的恶心和呕吐（CINV）仍然是化疗最令人恐惧且预料之中的副作用。优化止吐治疗很重要，因为CINV会导致生活质量下降、医疗资源使用增加以及治疗依从性受损。证据表明了止吐建议是如何演变的，并提出了CINV管理中持续存在的问题和争议。
相似文献
1
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?化疗引起的恶心和呕吐：是时候更加强调恶心了吗？
Oncologist. 2015 Jun;20(6):576-83. doi: 10.1634/theoncologist.2014-0438. Epub 2015 May 6.
2
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.阿瑞匹坦预防儿童化疗引起的恶心和呕吐的随机、双盲、3 期临床试验。
Lancet Oncol. 2015 Apr;16(4):385-94. doi: 10.1016/S1470-2045(15)70061-6. Epub 2015 Mar 12.
3
Evaluating Chemotherapy-induced Nausea and Vomiting and Food Intake in Patients With Gynecologic Cancer.评估妇科癌症患者化疗引起的恶心呕吐及食物摄入量
Anticancer Res. 2019 Aug;39(8):4555-4560. doi: 10.21873/anticanres.13633.
4
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.评估每间隔一天使用帕洛诺司琼的给药方案对多日高剂量化疗中呕吐的控制效果。
Future Oncol. 2014 Dec;10(16):2569-78. doi: 10.2217/fon.14.132.
5
Frequency of nausea and vomiting after chemotherapy.化疗后恶心和呕吐的发生率。
Am J Health Syst Pharm. 2004 Apr 1;61(7):722-3. doi: 10.1093/ajhp/61.7.722.
6
Prognostic factors for chemotherapy induced nausea and vomiting.化疗引起的恶心和呕吐的预后因素。
Eur J Pharmacol. 2014 Jan 5;722:192-6. doi: 10.1016/j.ejphar.2013.10.015. Epub 2013 Oct 21.
7
Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.格拉司琼与多西拉敏用于高度和中度高度致吐性化疗中急性化疗引起的恶心和呕吐（CINV）：一项开放标签的试点研究。
Curr Med Res Opin. 2004 Jun;20(6):879-82. doi: 10.1185/030079904125003728.
8
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.化疗引起的恶心和呕吐的预防性止吐治疗
N Engl J Med. 2016 Apr 7;374(14):1356-67. doi: 10.1056/NEJMra1515442.
9
Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines.化疗所致恶心和呕吐：三种共识指南概述与比较。
Postgrad Med J. 2016 Jan;92(1083):34-40. doi: 10.1136/postgradmedj-2014-132969. Epub 2015 Nov 11.
10
Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients.化疗患者预期性恶心和呕吐的患病率及其相关因素
J Natl Cancer Inst. 1982 Apr;68(4):585-8.
引用本文的文献
1
Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for grade 2 or higher emesis.奈妥匹坦帕洛诺司琼（NEPA）预防接受高致吐性化疗的癌症患者化疗引起的恶心和呕吐的疗效以及添加奥氮平治疗2级或更高级别呕吐的有效性。
Medicine (Baltimore). 2025 Jul 11;104(28):e43210. doi: 10.1097/MD.0000000000043210.
2
Fosaprepitant for the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.磷丙泊酚预防多日顺铂化疗所致恶心和呕吐的前瞻性随机对照研究。
BMC Pharmacol Toxicol. 2025 Jul 1;26(1):126. doi: 10.1186/s40360-025-00964-6.
3
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.奥氮平联合三联止吐方案预防卡铂所致恶心呕吐的随机、双盲、安慰剂对照 III 期临床研究。
J Clin Oncol. 2024 Aug 10;42(23):2780-2789. doi: 10.1200/JCO.24.00278. Epub 2024 Jun 4.
4
2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients.2020 年 ASCO、2023 年 NCCN、2023 年 MASCC/ESMO 和 2019 年 CCO：癌症患者化疗所致恶心呕吐治疗中止吐指南的比较。
Support Care Cancer. 2024 Apr 10;32(5):280. doi: 10.1007/s00520-024-08462-x.
5
Antiemetic activity of abietic acid possibly through the 5HT and muscarinic receptors interaction pathways.松香酸的止吐活性可能是通过 5-HT 和毒蕈碱受体相互作用途径实现的。
Sci Rep. 2024 Mar 19;14(1):6642. doi: 10.1038/s41598-024-57173-0.
6
Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.奈妥匹坦/帕洛诺司琼与5-羟色胺-3受体拮抗剂预防造血干细胞移植患者化疗引起的恶心和呕吐的比较。
Front Oncol. 2023 Nov 21;13:1280336. doi: 10.3389/fonc.2023.1280336. eCollection 2023.
7
Olanzapine for The Prevention of Nausea and Vomiting Caused by Chemoradiotherapy with High-Dose Cisplatin for Head and Neck Cancer.奥氮平预防大剂量顺铂同步放化疗所致头颈部癌恶心呕吐的疗效观察
Yonago Acta Med. 2023 Apr 20;66(2):208-213. doi: 10.33160/yam.2023.05.002. eCollection 2023 May.
8
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal.评估葡萄牙接受 MEC 或 HEC 方案治疗的患者当前止吐治疗反应。
Curr Oncol. 2023 Jan 24;30(2):1529-1537. doi: 10.3390/curroncol30020117.
9
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.验证不同化疗所致恶心呕吐的个体化风险模型：一项随机、双盲、III 期临床试验中福沙匹坦用于接受高剂量顺铂治疗的癌症患者的结果。
Cancer Commun (Lond). 2023 Feb;43(2):246-256. doi: 10.1002/cac2.12397. Epub 2022 Dec 22.
10
Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial.中药配方对转移性结直肠癌患者无进展生存期的影响：一项多中心、双盲、随机、安慰剂对照试验的研究方案。
PLoS One. 2022 Dec 16;17(12):e0275058. doi: 10.1371/journal.pone.0275058. eCollection 2022.
本文引用的文献
1
Aprepitant versus dexamethasone to prevent delayed emesis after chemotherapy.阿瑞匹坦与地塞米松预防化疗后迟发性呕吐的比较。
J Clin Oncol. 2014 Jul 10;32(20):2184-5. doi: 10.1200/JCO.2014.55.3503. Epub 2014 Jun 9.
2
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.一项随机III期研究，评估奈妥匹坦和帕洛诺司琼固定剂量组合制剂NEPA预防中度致吐性化疗后化疗引起的恶心和呕吐的疗效及安全性。
Ann Oncol. 2014 Jul;25(7):1328-1333. doi: 10.1093/annonc/mdu101. Epub 2014 Mar 5.
3
Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.运用联合分析评估乳腺癌患者对化疗副作用的偏好。
Oncologist. 2014 Feb;19(2):127-34. doi: 10.1634/theoncologist.2013-0359. Epub 2014 Jan 28.
4
Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.阿瑞匹坦对比地塞米松预防乳腺癌患者化疗所致延迟性恶心：一项随机、双盲研究。
J Clin Oncol. 2014 Jan 10;32(2):101-6. doi: 10.1200/JCO.2013.51.4547. Epub 2013 Dec 9.
5
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.含昂丹司琼与帕洛诺司琼止吐方案预防高致吐性化疗的初步研究。
Support Care Cancer. 2013 Oct;21(10):2845-51. doi: 10.1007/s00520-013-1865-9. Epub 2013 Jun 8.
6
Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.前瞻性验证急性和延迟化疗诱导的恶心和呕吐的风险预测指标。
Curr Oncol. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.
7
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer.一项关于在乳腺癌辅助化疗后继续使用地塞米松超过 24 小时对生活质量影响的随机双盲安慰剂对照交叉试验。
Breast Cancer Res Treat. 2012 Nov;136(1):143-51. doi: 10.1007/s10549-012-2205-3. Epub 2012 Sep 6.
8
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.预防延迟性恶心：罗彻斯特大学癌症中心社区肿瘤临床方案对接受化疗患者的研究。
J Clin Oncol. 2012 Sep 20;30(27):3389-95. doi: 10.1200/JCO.2011.39.8123. Epub 2012 Aug 20.
9
Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.一种用于识别化疗引起的恶心和呕吐高危患者的预测工具的前瞻性验证。
J Support Oncol. 2013 Mar;11(1):14-21. doi: 10.1016/j.suponc.2012.05.001.
10
Antiemesis.止吐
J Natl Compr Canc Netw. 2012 Apr;10(4):456-85. doi: 10.6004/jnccn.2012.0047.
Zotero 插件